SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 6,640 shares, a decline of 78.9% from the August 15th total of 31,402 shares. Based on an average daily volume of 300,155 shares, the days-to-cover ratio is presently 0.0 days.
SAB Biotherapeutics Price Performance
Shares of SAB Biotherapeutics stock opened at $0.02 on Friday. SAB Biotherapeutics has a 52-week low of $0.00 and a 52-week high of $0.20. The business’s 50 day simple moving average is $0.02 and its 200 day simple moving average is $0.02.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
Further Reading
- Five stocks we like better than SAB Biotherapeutics
- Microsoft’s Azure Reporting Shift Adds Clarity, But the Bull Case Came First
- Feed to Feat: Can Meta Unlock the AI Agent Cash Machine?
- Chime Finds Its Stride With a $590M Deal That Could Reshape Its Banking Model
- IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
